Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 May 15;90(10):4332–4333. doi: 10.1073/pnas.90.10.4332

Tumor immunogenicity: how far can it be pushed?

R T Prehn 1
PMCID: PMC46503  PMID: 8506268

Full text

PDF
4332

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews E. J. Failure of immunosurveillance against chemically induced in situ tumors in mice. J Natl Cancer Inst. 1974 Mar;52(3):729–732. doi: 10.1093/jnci/52.3.729. [DOI] [PubMed] [Google Scholar]
  2. Bartlett G. L. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst. 1972 Aug;49(2):493–504. [PubMed] [Google Scholar]
  3. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. KLEIN G., SJOGREN H. O., KLEIN E., HELLSTROM K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960 Dec;20:1561–1572. [PubMed] [Google Scholar]
  6. Lawler E. M., Prehn R. T. Influence of immune status of host on immunogenicity of tumors induced with two doses of methylcholanthrene. Cancer Immunol Immunother. 1982;13(3):194–197. doi: 10.1007/BF00205388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Outzen H. C. Development of carcinogen-induced skin tumors in mice with varied states of immune capacity. Int J Cancer. 1980 Jul 15;26(1):87–92. doi: 10.1002/ijc.2910260114. [DOI] [PubMed] [Google Scholar]
  8. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  9. Plautz G. E., Yang Z. Y., Wu B. Y., Gao X., Huang L., Nabel G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4645–4649. doi: 10.1073/pnas.90.10.4645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Prehn R. T. Immunostimulation of chemical oncogenesis in the mouse. Int J Cancer. 1977 Dec 15;20(6):918–922. doi: 10.1002/ijc.2910200615. [DOI] [PubMed] [Google Scholar]
  11. Prehn R. T., Prehn L. M. The autoimmune nature of cancer. Cancer Res. 1987 Feb 15;47(4):927–932. [PubMed] [Google Scholar]
  12. Prehn R. T., Prehn L. M. The flip side of tumor immunity. Arch Surg. 1989 Jan;124(1):102–106. doi: 10.1001/archsurg.1989.01410010112022. [DOI] [PubMed] [Google Scholar]
  13. Prehn R. T. Relationship of tumor immunogenicity to concentration of the oncogen. J Natl Cancer Inst. 1975 Jul;55(1):189–190. doi: 10.1093/jnci/55.1.189. [DOI] [PubMed] [Google Scholar]
  14. Slemmer G. Host response to premalignant mammary tissues. Natl Cancer Inst Monogr. 1972 Dec;35:57–71. [PubMed] [Google Scholar]
  15. Stutman O. Immunodepression and malignancy. Adv Cancer Res. 1975;22:261–422. doi: 10.1016/s0065-230x(08)60179-7. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES